{"entity":{"id":"nct07652073","kind":"trial","name":"A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer","aka":[],"tldr":"A phase 2 trial of DAT-2645 run by Danatlas Pharmaceuticals Co., Ltd, not yet recruiting.","summary":"A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer is a phase 2 interventional study registered as NCT07652073 by Danatlas Pharmaceuticals Co., Ltd, with 30 participants planned, started 2026-06-15. Conditions recorded: Advanced or Metastatic Ovarian Cancer. Interventions recorded: DAT-2645 tablet.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07652073","url":"https://clinicaltrials.gov/study/NCT07652073"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["dat-2645"],"companies":["danatlas-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07652073","phase":"2","setting":"A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of DAT-2645 in Patients With BRCA1/2 Deleterious Mutations or HRD-Positive Advanced/Metastatic Ovarian Cancer","sponsor":"Danatlas Pharmaceuticals Co., Ltd","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07652073/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"dat-2645","kind":"drug","name":"DAT-2645","route":"/drugs/dat-2645/"}],"company":[{"id":"danatlas-pharmaceuticals","kind":"company","name":"Danatlas Pharmaceuticals","route":"/companies/danatlas-pharmaceuticals/"}]}}